30 closest matches · ranked by relevance
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. — 131; 131; 131; 131 Participants
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Hepatitis B · Polio · Diphtheria
Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)…
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Adolescent Immunizations · Preventive Care
Primary: Receipt of Adolescent Immunization at End of Study Period (Tdap, Menactra, HPV) — 1091; 885; 1783; 1367 participants
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate
Diphtheria · Tetanus · Pertussis
Primary: Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio…
Hepatitis B Vaccine
Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination — 95; 99; 55; 99 Percentage of…
Rabies
Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
Meningococcal Infection
Primary: Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at…
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants
Influenza
Primary: Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects — 329.76; 334.98; 334.98; 401.21 titers
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
Autoimmune Rheumatologic Disease
Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L
Hepatitis A
Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine…
Influenza · Orthomyxoviridae Infections
Primary: Number of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination 1 — 10; 2; 2; 1 Participants
Hepatitis B Vaccine
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 59; 62 Participants
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Diphtheria · Polio · Pertussis
Primary: Percentage of Participants With Pre-booster Antibody Persistence and Booster Response to DTaP-IPV-Hep B-PRP~T After Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T…